As Plan S Takes Effect, Some Anticipate Inequitable Outcomes

The plan’s signatories seek to make the results of their funded research available to all, but some scientists say the transition to open access has led to climbing publication fees and could exacerbate global disparities.

Written byAlejandra Manjarrez, PhD
| 7 min read
black and white image of an open combination lock with a globe in the middle

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

ABOVE: © ISTOCK.COM, XPOINT

In the three years since its announcement, Plan S, an initiative dedicated to making scientific research publicly available, has attracted new members, including international organizations and government funding agencies from around the world. A number of researchers question the global impact of Plan S’s implementation, however, raising concerns that its stringent open-access mandates have contributed to an increase in associated publishing costs that could potentially cut into research budgets and exacerbate inequalities that already exist in science publishing.

Plan S is a set of requirements drafted in September 2018 by a newly formed group of 11 national funding agencies across Europe collectively dubbed cOAlition S and supported by the European Commission and, initially, the European Research Council. The group aims to end the reign of paywalls and promote a transition to a fully open-access publishing model in science.

Traditionally, scientific journals have been sustained by subscriptions ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • alejandra manjarrez

    Alejandra Manjarrez is a freelance science journalist who contributes to The Scientist. She has a PhD in systems biology from ETH Zurich and a master’s in molecular biology from Utrecht University. After years studying bacteria in a lab, she now spends most of her days reading, writing, and hunting science stories, either while traveling or visiting random libraries around the world. Her work has also appeared in Hakai, The Atlantic, and Lab Times.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies